Hassouna H, Singh D: Morton's metatarsalgia: pathogenesis, aetiology and current management. Acta Orthop Belg 71: 646, 2005.
Wu KK: Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. J Foot Ankle Surg 35: 112, 1996.
Morscher E, Ulrich J, Dick W: Morton's intermetatarsal neuroma: morphology and histological substrate. Foot Ankle Int 21: 558, 2000.
Mulder JD: The causative mechanism in morton's metatarsalgia. J Bone Joint Surg Br 33: 94, 1951.
Lee MJ, Kim S, Huh YM, et al: Morton neuroma: evaluated with ultrasonography and MR imaging. Korean J Radiol 8: 148, 2007.
Dockery GL: The treatment of intermetatarsal neuromas with 4% alcohol sclerosing injections. J Foot Ankle Surg 38: 403, 1999.
Reddy PD, Zelicof SB, Ruotolo C, et al: Interdigital neuroma: local cutaneous changes after corticosteroid injection. Clin Orthop Relat Res 317: 185, 1995.
Lee KT, Kim JB, Young KW, et al: Long-term results of neurectomy in the treatment of Morton's neuroma: more than 10 years' follow-up. Foot Ankle Spec 4: 349, 2011.
Haupt G, Chvapil M: Effect of shock waves on the healing of partial-thickness wounds in piglets. J Surg Res 49: 45, 1990.
Mariotto S, de Prati AC, Cavalieri E, et al: Extracorporeal shock wave therapy in inflammatory diseases: molecular mechanism that triggers anti-inflammatory action. Curr Med Chem 16: 2366, 2009.
Ciampa AR, de Prati AC, Amelio E, et al: Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS Lett 579: 6839, 2005.
Ohtori S, Inoue G, Mannoji C, et al: Shock wave application to rat skin induces degeneration and reinnervation of sensory nerve fibres. Neurosci Lett 315: 57, 2001.
Hausdorf J, Lemmens MA, Kaplan S, et al: Extracorporeal shockwave application to the distal femur of rabbits diminishes the number of neurons immunoreactive for substance P in dorsal root ganglia L5. Brain Res 1207: 96, 2008.
Hausdorf J, Lemmens MA, Heck KD, et al: Selective loss of unmyelinated nerve fibers after extracorporeal shockwave application to the musculoskeletal system. Neuroscience 155: 138, 2008.
Galeazza MT, Garry MG, Yost HJ, et al: Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience 66: 443, 1995.
Zochodne DW, Theriault M, Sharkey KA, et al: Peptides and neuromas: calcitonin gene-related peptide, substance P, and mast cells in a mechanosensitive human sural neuroma. Muscle Nerve 20: 875, 1997.
Lindqvist A, Rivero-Melian C, Turan I, et al: Neuropeptide- and tyrosine hydroxylase-immunoreactive nerve fibers in painful Morton's neuromas. Muscle Nerve 23: 1214, 2000.
Holzer P: Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24: 739, 1988.
Hughes RJ, Ali K, Jones H, et al: Treatment of Morton's neuroma with alcohol injection under sonographic guidance: follow-up of 101 cases. AJR Am J Roentgenol 188: 1535, 2007.
Rengachary SS, Watanabe IS, Singer P, et al: Effect of glycerol on peripheral nerve: an experimental study. Neurosurgery 13: 681, 1983.
Makki D, Haddad BZ, Mahmood Z, et al: Efficacy of corticosteroid injection versus size of plantar interdigital neuroma. Foot Ankle Int 33: 722, 2012.
Background: The aim of this study was to evaluate the efficacy of extracorporeal shockwave therapy (ESWT) for the treatment of Morton's neuroma by measuring changes in patient pain, function, and neuroma size.
Methods: Patients with Morton's neuroma were randomly assigned to either the ESWT group or the sham stimulation group. Outcome measures, including visual analog scale (VAS) and American Orthopaedic Foot and Ankle Society lesser toes (AOFAS) scores, were assessed at baseline and 1 and 4 weeks after treatment. The Johnson satisfaction test was also performed 1 and 4 weeks after treatment. The neuroma diameter was measured using ultrasonography at baseline and 4 weeks after treatment.
Results: Patients receiving ESWT exhibited significantly decreased VAS scores 1 and 4 weeks after treatment relative to baseline, and AOFAS scores were significantly improved 4 weeks after treatment relative to baseline. In the sham stimulation group, VAS and AOFAS scores showed no significant changes at any time after treatment. Neither group showed significant changes in Johnson satisfaction test results or neuroma diameter.
Conclusions: These results suggest that ESWT may reduce pain in patients with Morton's neuroma.